Toll Free: 1-888-928-9744
Published: Aug, 2014 | Pages:
41 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Herpes Labialis (Oral Herpes) - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Herpes Labialis (Oral Herpes) - Pipeline Review, H2 2014', provides an overview of the Herpes Labialis (Oral Herpes)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Herpes Labialis (Oral Herpes), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Labialis (Oral Herpes) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Herpes Labialis (Oral Herpes) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Herpes Labialis (Oral Herpes) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Herpes Labialis (Oral Herpes) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Herpes Labialis (Oral Herpes) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Herpes Labialis (Oral Herpes) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Herpes Labialis (Oral Herpes) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Herpes Labialis (Oral Herpes) Overview 6 Therapeutics Development 7 Pipeline Products for Herpes Labialis (Oral Herpes) - Overview 7 Pipeline Products for Herpes Labialis (Oral Herpes) - Comparative Analysis 8 Herpes Labialis (Oral Herpes) - Therapeutics under Development by Companies 9 Herpes Labialis (Oral Herpes) - Pipeline Products Glance 10 Late Stage Products 10 Clinical Stage Products 11 Early Stage Products 12 Herpes Labialis (Oral Herpes) - Products under Development by Companies 13 Herpes Labialis (Oral Herpes) - Companies Involved in Therapeutics Development 14 NanoViricides, Inc. 14 Foamix Ltd. 15 Beech Tree Labs, Inc. 16 Herpes Labialis (Oral Herpes) - Therapeutics Assessment 17 Assessment by Monotherapy Products 17 Assessment by Target 18 Assessment by Mechanism of Action 19 Assessment by Route of Administration 20 Assessment by Molecule Type 22 Drug Profiles 24 acyclovir - Drug Profile 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 BTL-TMLHSV - Drug Profile 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 ZEP-3 - Drug Profile 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 HerpeCide-I - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 acyclovir - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Herpes Labialis (Oral Herpes) - Recent Pipeline Updates 30 Herpes Labialis (Oral Herpes) - Dormant Projects 33 Herpes Labialis (Oral Herpes) - Product Development Milestones 34 Featured News & Press Releases 34 Jul 21, 2014: BioAlliance Pharma announces the launch of Sitavig in the United States by its partner Innocutis and the granting of a new U.S. Sitavig patent 34 Jul 10, 2013: BioAlliance Pharma expands and strengthens its industrial property assets with two patent grants 34 May 27, 2013: BioAlliance Pharma Presents Results Of Sitavig At 10th EADV Symposium 35 Apr 15, 2013: BioAlliance Pharma's Sitavig Receives US Marketing Authorization For Treatment Of Herpes Labialis 35 Apr 04, 2013: Beech Tree Labs Successfully Completes IND Phase I/IIa Oral Herpes Clinical Trial 36 Jul 26, 2012: BioAlliance Pharma Receives US Patent Covering Sitavig 37 May 29, 2012: BioAlliance Announces Receivability Of Sitavig US Registration Dossier 37 Oct 05, 2011: BioAlliance Submits Sitavir European Registration Dossier Through European Decentralized Procedure 38 Feb 07, 2011: BioAlliance Pharma Presents Results Of International Survey Performed With Nielsen In Patients Suffering From Herpes Labialis 38 Nov 17, 2010: BioAlliance Pharma Presents Pharmacokinetic Results Of Sitavir At AAPS Annual Meeting 39 Appendix 40 Methodology 40 Coverage 40 Secondary Research 40 Primary Research 40 Expert Panel Validation 40 Contact Us 41 Disclaimer 41
List of Tables Number of Products under Development for Herpes Labialis (Oral Herpes), H2 2014 7 Number of Products under Development for Herpes Labialis (Oral Herpes) - Comparative Analysis, H2 2014 8 Number of Products under Development by Companies, H2 2014 9 Comparative Analysis by Late Stage Development, H2 2014 10 Comparative Analysis by Clinical Stage Development, H2 2014 11 Comparative Analysis by Early Stage Development, H2 2014 12 Products under Development by Companies, H2 2014 13 Herpes Labialis (Oral Herpes) - Pipeline by NanoViricides, Inc., H2 2014 14 Herpes Labialis (Oral Herpes) - Pipeline by Foamix Ltd., H2 2014 15 Herpes Labialis (Oral Herpes) - Pipeline by Beech Tree Labs, Inc., H2 2014 16 Assessment by Monotherapy Products, H2 2014 17 Number of Products by Stage and Target, H2 2014 18 Number of Products by Stage and Mechanism of Action, H2 2014 19 Number of Products by Stage and Route of Administration, H2 2014 21 Number of Products by Stage and Molecule Type, H2 2014 23 Herpes Labialis (Oral Herpes) Therapeutics - Recent Pipeline Updates, H2 2014 30 Herpes Labialis (Oral Herpes) - Dormant Projects, H2 2014 33
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.